The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LVIII.au

Path: Airway inflammation

Publications

Horibe R, Hashimoto M, Nishiyama K

Bronchiolitis of immune checkpoint inhibitor therapy-related pneumonitis.

The American journal of the medical sciences 2022 Sep 23;; — 2022 Sep 23

Yamaya T, Hee HM, Aoyagi T, Ogimoto T, Yamada N, Ishikawa R, Nakai E, Nishi K, Yoshimura C, Nishizaka Y

Pembrolizumab-associated bronchiolitis in an elderly lung cancer patient required the treatment with an inhaled corticosteroid, erythromycin and bronchodilators.

Respiratory medicine case reports 2019;28;100866 — 2019 — 100866

Ogawa T, Miyata J, Maehara J, Inoue T, Betsuyaku T

Fatal Airway Inflammation Induced by Pembrolizumab in a Patient With NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019 Jan;14;e9-e10 — 2019 Jan — e9-e10

Sehgal S, Velcheti V, Mukhopadhyay S, Stoller JK

Focal lung infiltrate complicating PD-1 inhibitor use: A new pattern of drug-associated lung toxicity?

Respiratory medicine case reports 2016;19;118-20 — 2016 — 118-20